XML 26 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Cash Flows ( Unaudited) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2017
Sep. 30, 2016
Cash flows from operating activities:    
Net income $ 50,495 $ 47,492
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 16,397 15,164
Amortization of deferred revenue (1,004) (843)
Amortization of deferred financing costs and debt discount 1,438 1,095
Accretion of asset retirement obligations 219 199
Deferred income taxes 158 0
(Income) loss from equity method investments (3,005) 743
Dividends from equity method investments 1,518 0
Loss (gain) on asset disposals 2 (16)
Unit-based compensation expense 545 414
Changes in assets and liabilities:    
Accounts receivable (1,115) 21,557
Inventories and other current assets 2,028 3,808
Accounts payable and other current liabilities 8,501 775
Accounts receivable/payable to related parties 2,092 (4,110)
Non-current assets and liabilities, net (365) 483
Net cash provided by operating activities 77,904 86,761
Cash flows from investing activities:    
Asset acquisitions (6,443) 0
Purchases of property, plant and equipment (9,187) (5,633)
Proceeds from sales of property, plant and equipment 0 175
Purchases of intangible assets (2,560) 0
Equity method investment contributions (3,531) (54,703)
Net cash used in investing activities (21,721) (60,161)
Cash flows from financing activities:    
Proceeds from issuance of additional units to maintain 2% General Partner interest 21 15
Distributions to general partner (12,839) (6,861)
Distributions to common unitholders - public (19,208) (17,601)
Distributions to common unitholders - Delek (31,555) (15,578)
Distributions to subordinated unitholders - Delek 0 (11,503)
Proceeds from revolving credit facility 205,700 229,150
Payments of revolving credit facility (439,500) (205,750)
Proceeds from issuance of senior notes 248,112 0
Deferred financing costs paid (5,937) 0
Reimbursement of capital expenditures by Delek 4,254 1,528
Net cash used in financing activities (50,952) (26,600)
Net increase in cash and cash equivalents 5,231 0
Cash and cash equivalents at the beginning of the period 59 0
Cash and cash equivalents at the end of the period 5,290 0
Cash paid during the period for:    
Interest 9,288 8,902
Income taxes 60 0
Non-cash investing activities:    
Decrease in accrued capital expenditures (491) (624)
Non-cash financing activities:    
Sponsor contribution of fixed assets $ 67 $ 609